B
Bull
Bull · 25%MTSR
$41.40
Precio del escenario
$70.500
-0.247 (-0.35%)Al cierre
Loading chart…
- High
- 70.780
- Open
- 70.740
- VWAP
- 70.47
- Vol
- 27.91M
- Mkt Cap
- —
- Low
- 70.130
- Amount
- 1.97B
- EV/EBITDA, TTM
- -8.94
Metsera, Inc. is a clinical-stage biopharmaceutical company, which is developing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies. The Company uses its proprietary MINT peptide library of nutrient stimulated hormone (NuSH) analog peptides alongside its half-life augmentation by lipid optimization (HALO) half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver differentiated product candidates. Its product pipeline includes MET-097i, MET-233i, MET-233i + MET-097i, MET-097o/MET-224o, MET-002o, MET-034i, MET-067i, and MET-815i. The Company's additional pipeline includes MET-815i, MET-AMYo, MET-034i, MET-067i and MET-PYYi. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides.
Métricas de valoración
The current forward P/E ratio for Metsera Inc (MTSR) is -8.88, compared to its 5-year average forward P/E of -10.50.
Alphio AI Price Scenarios for MTSR
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding MTSR
Cronología de eventos
Noticias
8.502-18stocktwitsCormorant Increases MoonLake Stake Above 6%
7.012-16BenzingaPfizer Anticipates Slower Growth in 2026 Despite Efforts to Enhance Pipeline and Reduce Costs
2.011-21TipRanksNovo Nordisk Shares Face Challenges as Competitor Eli Lilly Enters the $1 Trillion Market Valuation Club
8.511-14BenzingaMarket Update: Warner Bros., Bill.com, C3 AI—Significant Auctions and Acquisitions Impact the Industry
5.011-14BenzingaNovo Nordisk, the Manufacturer of Ozempic, Encounters Board Restructuring
MTSR FAQ — answered by Alphio AI
Metsera, Inc. is a clinical-stage biopharmaceutical company, which is developing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies. The Company uses its proprietary MINT peptide library of nutrient stimulated hormone (NuSH) analog peptides alongside its half-life augmentation by lipid optimization (HALO) half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver differentiated product candidates. Its product pipeline includes MET-097i, MET-233i, MET-233i + MET-097i, MET-097o/MET-224o, MET-002o, MET-034i, MET-067i, and MET-815i. The Company's additional pipeline includes MET-815i, MET-AMYo, MET-034i, MET-067i and MET-PYYi. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides. It operates in the Healthcare sector.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.